VRCA vs. AMRN, TNGX, OCGN, KOD, CGC, ACRS, RZLT, FDMT, ALMS, and MDWD
Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Amarin (AMRN), Tango Therapeutics (TNGX), Ocugen (OCGN), Kodiak Sciences (KOD), Canopy Growth (CGC), Aclaris Therapeutics (ACRS), Rezolute (RZLT), 4D Molecular Therapeutics (FDMT), Alumis (ALMS), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry.
Verrica Pharmaceuticals vs.
Amarin (NASDAQ:AMRN) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations.
Verrica Pharmaceuticals has a consensus target price of $9.50, suggesting a potential upside of 1,823.08%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Amarin.
Amarin received 677 more outperform votes than Verrica Pharmaceuticals when rated by MarketBeat users. Likewise, 73.52% of users gave Amarin an outperform vote while only 63.74% of users gave Verrica Pharmaceuticals an outperform vote.
22.3% of Amarin shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 2.0% of Amarin shares are held by insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Amarin had 5 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 6 mentions for Amarin and 1 mentions for Verrica Pharmaceuticals. Amarin's average media sentiment score of 0.28 beat Verrica Pharmaceuticals' score of -1.00 indicating that Amarin is being referred to more favorably in the media.
Amarin has a net margin of -16.33% compared to Verrica Pharmaceuticals' net margin of -625.06%. Amarin's return on equity of -7.22% beat Verrica Pharmaceuticals' return on equity.
Amarin has higher revenue and earnings than Verrica Pharmaceuticals. Amarin is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amarin has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.
Summary
Amarin beats Verrica Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Verrica Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verrica Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRCA) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy VRCA Stock Free VRCA Stock Alerts